Cargando…

Dapagliflozin/Hesperidin Combination Mitigates Lipopolysaccharide-Induced Alzheimer’s Disease in Rats

Alzheimer’s disease (AD) is the most common form of neurodegenerative disorders worldwide. Its pathologic features include massive neuroinflammation with abnormal deposition of β-amyloid peptide in the cerebral tissues leading to degeneration of the brain neurons. Adverse effects associated with the...

Descripción completa

Detalles Bibliográficos
Autores principales: Abd Elmaaboud, Maaly A., Estfanous, Remon S., Atef, Aliaa, Kabel, Ahmed M., Alnemari, Khalid A., Naguib, Tamer M., Alsufyani, Shuruq E., Darwish, Hany W., Arab, Hany H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609711/
https://www.ncbi.nlm.nih.gov/pubmed/37895841
http://dx.doi.org/10.3390/ph16101370
_version_ 1785128077047627776
author Abd Elmaaboud, Maaly A.
Estfanous, Remon S.
Atef, Aliaa
Kabel, Ahmed M.
Alnemari, Khalid A.
Naguib, Tamer M.
Alsufyani, Shuruq E.
Darwish, Hany W.
Arab, Hany H.
author_facet Abd Elmaaboud, Maaly A.
Estfanous, Remon S.
Atef, Aliaa
Kabel, Ahmed M.
Alnemari, Khalid A.
Naguib, Tamer M.
Alsufyani, Shuruq E.
Darwish, Hany W.
Arab, Hany H.
author_sort Abd Elmaaboud, Maaly A.
collection PubMed
description Alzheimer’s disease (AD) is the most common form of neurodegenerative disorders worldwide. Its pathologic features include massive neuroinflammation with abnormal deposition of β-amyloid peptide in the cerebral tissues leading to degeneration of the brain neurons. Adverse effects associated with the traditional drugs used for the treatment of this pathological condition have directed the research efforts towards searching for alternative effective agents with minimal adverse effects. The aim of this study was to elucidate the potential ameliorative effects of dapagliflozin and/or hesperidin on Alzheimer’s disease (AD) induced by lipopolysaccharide (LPS) injection in rats. In a rodent model of AD, the effect of dapagliflozin with or without hesperidin on the biochemical parameters and the behavioral tests as well as the histopathological parameters was determined. Each of dapagliflozin and hesperidin restored the behavioral tests to the reference values, augmented the antioxidant defense mechanisms, ameliorated the neuronal inflammatory responses, combatted the changes in Toll-like receptor-4 (TLR-4)/High-mobility group box 1 (HMGB1) protein signaling and receptors of advanced glycation end products (RAGE) levels, and restored the balance between the apoptotic signals and autophagy in the hippocampal tissues. Additionally, both agents exhibited an outstanding ability to combat LPS-induced perturbations in the histopathological and electron microscopic image of the brain tissues. These favorable effects were significantly encountered in the group treated with dapagliflozin/hesperidin combination when compared versus animals treated with either dapagliflozin or hesperidin. In conclusion, inhibition of the hippocampal HMGB1/TLR4/RAGE signaling, the pro-inflammatory axis, and apoptosis alongside augmentation of the antioxidant defenses and autophagy can be regarded as beneficial effects by which dapagliflozin/hesperidin combination may combat LPS-triggered AD.
format Online
Article
Text
id pubmed-10609711
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106097112023-10-28 Dapagliflozin/Hesperidin Combination Mitigates Lipopolysaccharide-Induced Alzheimer’s Disease in Rats Abd Elmaaboud, Maaly A. Estfanous, Remon S. Atef, Aliaa Kabel, Ahmed M. Alnemari, Khalid A. Naguib, Tamer M. Alsufyani, Shuruq E. Darwish, Hany W. Arab, Hany H. Pharmaceuticals (Basel) Article Alzheimer’s disease (AD) is the most common form of neurodegenerative disorders worldwide. Its pathologic features include massive neuroinflammation with abnormal deposition of β-amyloid peptide in the cerebral tissues leading to degeneration of the brain neurons. Adverse effects associated with the traditional drugs used for the treatment of this pathological condition have directed the research efforts towards searching for alternative effective agents with minimal adverse effects. The aim of this study was to elucidate the potential ameliorative effects of dapagliflozin and/or hesperidin on Alzheimer’s disease (AD) induced by lipopolysaccharide (LPS) injection in rats. In a rodent model of AD, the effect of dapagliflozin with or without hesperidin on the biochemical parameters and the behavioral tests as well as the histopathological parameters was determined. Each of dapagliflozin and hesperidin restored the behavioral tests to the reference values, augmented the antioxidant defense mechanisms, ameliorated the neuronal inflammatory responses, combatted the changes in Toll-like receptor-4 (TLR-4)/High-mobility group box 1 (HMGB1) protein signaling and receptors of advanced glycation end products (RAGE) levels, and restored the balance between the apoptotic signals and autophagy in the hippocampal tissues. Additionally, both agents exhibited an outstanding ability to combat LPS-induced perturbations in the histopathological and electron microscopic image of the brain tissues. These favorable effects were significantly encountered in the group treated with dapagliflozin/hesperidin combination when compared versus animals treated with either dapagliflozin or hesperidin. In conclusion, inhibition of the hippocampal HMGB1/TLR4/RAGE signaling, the pro-inflammatory axis, and apoptosis alongside augmentation of the antioxidant defenses and autophagy can be regarded as beneficial effects by which dapagliflozin/hesperidin combination may combat LPS-triggered AD. MDPI 2023-09-27 /pmc/articles/PMC10609711/ /pubmed/37895841 http://dx.doi.org/10.3390/ph16101370 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Abd Elmaaboud, Maaly A.
Estfanous, Remon S.
Atef, Aliaa
Kabel, Ahmed M.
Alnemari, Khalid A.
Naguib, Tamer M.
Alsufyani, Shuruq E.
Darwish, Hany W.
Arab, Hany H.
Dapagliflozin/Hesperidin Combination Mitigates Lipopolysaccharide-Induced Alzheimer’s Disease in Rats
title Dapagliflozin/Hesperidin Combination Mitigates Lipopolysaccharide-Induced Alzheimer’s Disease in Rats
title_full Dapagliflozin/Hesperidin Combination Mitigates Lipopolysaccharide-Induced Alzheimer’s Disease in Rats
title_fullStr Dapagliflozin/Hesperidin Combination Mitigates Lipopolysaccharide-Induced Alzheimer’s Disease in Rats
title_full_unstemmed Dapagliflozin/Hesperidin Combination Mitigates Lipopolysaccharide-Induced Alzheimer’s Disease in Rats
title_short Dapagliflozin/Hesperidin Combination Mitigates Lipopolysaccharide-Induced Alzheimer’s Disease in Rats
title_sort dapagliflozin/hesperidin combination mitigates lipopolysaccharide-induced alzheimer’s disease in rats
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609711/
https://www.ncbi.nlm.nih.gov/pubmed/37895841
http://dx.doi.org/10.3390/ph16101370
work_keys_str_mv AT abdelmaaboudmaalya dapagliflozinhesperidincombinationmitigateslipopolysaccharideinducedalzheimersdiseaseinrats
AT estfanousremons dapagliflozinhesperidincombinationmitigateslipopolysaccharideinducedalzheimersdiseaseinrats
AT atefaliaa dapagliflozinhesperidincombinationmitigateslipopolysaccharideinducedalzheimersdiseaseinrats
AT kabelahmedm dapagliflozinhesperidincombinationmitigateslipopolysaccharideinducedalzheimersdiseaseinrats
AT alnemarikhalida dapagliflozinhesperidincombinationmitigateslipopolysaccharideinducedalzheimersdiseaseinrats
AT naguibtamerm dapagliflozinhesperidincombinationmitigateslipopolysaccharideinducedalzheimersdiseaseinrats
AT alsufyanishuruqe dapagliflozinhesperidincombinationmitigateslipopolysaccharideinducedalzheimersdiseaseinrats
AT darwishhanyw dapagliflozinhesperidincombinationmitigateslipopolysaccharideinducedalzheimersdiseaseinrats
AT arabhanyh dapagliflozinhesperidincombinationmitigateslipopolysaccharideinducedalzheimersdiseaseinrats